Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Aug;85(2):224–230. doi: 10.1111/j.1365-2249.1991.tb05709.x

T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.

M Herzog 1, C Fritzell 1, M Lafage 1, J A Montaño Hirose 1, D Scott-Algara 1, M Lafon 1
PMCID: PMC1535758  PMID: 1864001

Abstract

T and B cell human responses to European bat lyssavirus (EBL1) induced by post-exposure rabies vaccination (PM virus vaccine) were evaluated by measuring plasmatic titres of EBL1-specific neutralizing antibodies; specific EBL1-binding antibodies; and proliferation indices of peripheral blood lymphocytes stimulated in vitro with EBL1. These parameters for vaccination efficacy were compared with those obtained with vaccine-related viruses (CVS and ERA) and with a non-vaccine-related virus. Mokola virus, the last implicated in vaccination failures. Twenty-two patients exposed to rabies risk who received a reduced rabies post-exposure vaccination were involved in the study. On day 21, vaccine induced CVS-specific neutralizing antibodies in all patients; but EBL1-specific neutralizing antibodies were induced in only 73% of patients. No vaccine had Mokola-specific neutralizing antibodies. Patients having EBL1-specific neutralizing antibodies were usually those in whom vaccination induced high titres of CVS-specific neutralizing antibodies. On day 21, peripheral blood lymphocytes of 86% of patients could be restimulated in vitro with vaccine, 43% with EBL1 and 45% with Mokola. Patients exhibiting a high vaccine-specific proliferation response more likely developed an EBL1- or a Mokola-specific proliferative response. No correlation was found between T and B cell responses. Rabies vaccination induced neither T nor B cell EBL1-specific responses in 22% of patients.

Full text

PDF
224

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atanasiu P., Savy V., Perrin P. Epreuve immunoenzymatique pour la détection rapide des anticorps antirabiques. Ann Microbiol (Paris) 1977 May-Jun;128A(4):489–498. [PubMed] [Google Scholar]
  2. Bunschoten H., Klapmuts R. J., Claassen I. J., Reyneveld S. D., Osterhaus A. D., Uytdehaag F. G. Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein. J Gen Virol. 1989 Jun;70(Pt 6):1513–1521. doi: 10.1099/0022-1317-70-6-1513. [DOI] [PubMed] [Google Scholar]
  3. Celis E., Ou D., Dietzschold B., Koprowski H. Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients. J Virol. 1988 Sep;62(9):3128–3134. doi: 10.1128/jvi.62.9.3128-3134.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Charlton K. M., Casey G. A. Experimental rabies in skunks: immunofluorescence light and electron microscopic studies. Lab Invest. 1979 Jul;41(1):36–44. [PubMed] [Google Scholar]
  5. Dietzschold B., Rupprecht C. E., Tollis M., Lafon M., Mattei J., Wiktor T. J., Koprowski H. Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implications for epidemiology and control of rabies. Rev Infect Dis. 1988 Nov-Dec;10 (Suppl 4):S785–S798. doi: 10.1093/clinids/10.supplement_4.s785. [DOI] [PubMed] [Google Scholar]
  6. Dietzschold B., Tollis M., Rupprecht C. E., Celis E., Koprowski H. Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody. J Infect Dis. 1987 Nov;156(5):815–822. doi: 10.1093/infdis/156.5.815. [DOI] [PubMed] [Google Scholar]
  7. Dietzschold B., Wang H. H., Rupprecht C. E., Celis E., Tollis M., Ertl H., Heber-Katz E., Koprowski H. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9165–9169. doi: 10.1073/pnas.84.24.9165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Foggin C. M. Atypical rabies virus in cats and a dog in Zimbabwe. Vet Rec. 1982 Apr 3;110(14):338–338. doi: 10.1136/vr.110.14.338. [DOI] [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Lafon M., Bourhy H., Sureau P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice. Vaccine. 1988 Aug;6(4):362–368. doi: 10.1016/0264-410x(88)90184-3. [DOI] [PubMed] [Google Scholar]
  11. Lafon M., Edelman L., Bouvet J. P., Lafage M., Montchâtre E. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol. 1990 Aug;71(Pt 8):1689–1696. doi: 10.1099/0022-1317-71-8-1689. [DOI] [PubMed] [Google Scholar]
  12. Lafon M., Herzog M., Sureau P. Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage) Lancet. 1986 Aug 30;2(8505):515–515. doi: 10.1016/s0140-6736(86)90384-3. [DOI] [PubMed] [Google Scholar]
  13. Lumio J., Hillbom M., Roine R., Ketonen L., Haltia M., Valle M., Neuvonen E., Lähdevirta J. Human rabies of bat origin in Europe. Lancet. 1986 Feb 15;1(8477):378–378. doi: 10.1016/s0140-6736(86)92336-6. [DOI] [PubMed] [Google Scholar]
  14. Mifune K., Takeuchi E., Napiorkowski P. A., Yamada A., Sakamoto K. Essential Role of T cells in the postexposure prophylaxis of rabies in mice. Microbiol Immunol. 1981;25(9):895–904. doi: 10.1111/j.1348-0421.1981.tb00094.x. [DOI] [PubMed] [Google Scholar]
  15. Murphy F. A., Bauer S. P., Harrison A. K., Winn W. C., Jr Comparative pathogenesis of rabies and rabies-like viruses. Viral infection and transit from inoculation site to the central nervous system. Lab Invest. 1973 Mar;28(3):361–376. [PubMed] [Google Scholar]
  16. Nicholson K. G., Cole P. J., Turner G. S., Harrison P. Immune responses of humans to a human diploid cell strain of rabies virus vaccine: lymphocyte transformation, production of virus-neutralizing antibody, and induction of interferon. J Infect Dis. 1979 Aug;140(2):176–182. doi: 10.1093/infdis/140.2.176. [DOI] [PubMed] [Google Scholar]
  17. Ratanavongsiri J., Sriwanthana B., Ubol S., Phanuphak P. Cell-mediated immune response following intracutaneous immunisation with human diploid cell rabies vaccine. Asian Pac J Allergy Immunol. 1985 Dec;3(2):187–190. [PubMed] [Google Scholar]
  18. Sato M., Maeda N., Yoshida H., Urade M., Saito S. Plaque formation of herpes virus hominis type 2 and rubella virus in variants isolated from the colonies of BHK21/WI-2 cells formed in soft agar. Arch Virol. 1977;53(3):269–273. doi: 10.1007/BF01314672. [DOI] [PubMed] [Google Scholar]
  19. Schneider L. G. Antigenic variants of rabies virus. Comp Immunol Microbiol Infect Dis. 1982;5(1-3):101–107. doi: 10.1016/0147-9571(82)90021-2. [DOI] [PubMed] [Google Scholar]
  20. Schumacher C. L., Dietzschold B., Ertl H. C., Niu H. S., Rupprecht C. E., Koprowski H. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest. 1989 Sep;84(3):971–975. doi: 10.1172/JCI114260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Selimov M. A., Tatarov A. G., Botvinkin A. D., Klueva E. V., Kulikova L. G., Khismatullina N. A. Rabies-related Yuli virus; identification with a panel of monoclonal antibodies. Acta Virol. 1989 Dec;33(6):542–546. [PubMed] [Google Scholar]
  22. Smith J. S. Mouse model for abortive rabies infection of the central nervous system. Infect Immun. 1981 Jan;31(1):297–308. doi: 10.1128/iai.31.1.297-308.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Smith J. S., Yager P. A., Baer G. M. A rapid tissue culture test for determining rabies neutralizing antibody. Monogr Ser World Health Organ. 1973;(23):354–357. [PubMed] [Google Scholar]
  24. Turner G. S. Thymus dependence of rabies vaccine. J Gen Virol. 1976 Dec;33(3):535–538. doi: 10.1099/0022-1317-33-3-535. [DOI] [PubMed] [Google Scholar]
  25. Vodopija I., Sureau P., Smerdel S., Lafon M., Baklaić Z., Ljubicić M., Svjetlicić M. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine. 1988 Jun;6(3):283–286. doi: 10.1016/0264-410x(88)90225-3. [DOI] [PubMed] [Google Scholar]
  26. Wiktor T. J., Dietzschold B., Leamnson R. N., Koprowski H. Induction and biological properties of defective interfering particles of rabies virus. J Virol. 1977 Feb;21(2):626–635. doi: 10.1128/jvi.21.2.626-635.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wiktor T. J., György E., Schlumberger D., Sokol F., Koprowski H. Antigenic properties of rabies virus components. J Immunol. 1973 Jan;110(1):269–276. [PubMed] [Google Scholar]
  28. Wiktor T. J., Macfarlan R. I., Foggin C. M., Koprowski H. Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand. 1984;57:199–211. [PubMed] [Google Scholar]
  29. Zalan E., Wilson C., Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand. 1979 Jul;7(3):213–220. doi: 10.1016/s0092-1157(79)80024-4. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES